Berkenboom G, Brékine D, Unger P, Grosfils K, Staroukine M, Fontaine J
Department of Cardiology, Erasme Hospital, Brussels, Belgium.
Hypertension. 1995 Nov;26(5):738-43. doi: 10.1161/01.hyp.26.5.738.
To determine whether chronic angiotensin-converting enzyme (ACE) inhibition produces functional changes in the aorta normotensive rats, four groups of rats were studied in parallel for 6 weeks. Group 1 orally received ramipril and beta 2-kinin antagonist HOE140 500 micrograms/kg per day s.c. by injection for the remaining 2 weeks; group 3, hydralazine 100 mg/kg per day PO for 6 weeks; group 4 (control), subcutaneous injections of saline solution during the last 2 of 6 weeks. In aorta isolated from group 1 the relaxations induced by bradykinin, acetylcholine, and histamine were significantly potentiated compared with those of group 4. In group 3, despite a decrease in systolic blood pressure similar to that induced by ramipril treatment, the responses to these three endothelium-dependent vasodilators were not different from those of group 4. In group 2, bradykinin-induced relaxations were completely abolished whereas acetylcholine-induced and histamine-induced relaxations were to those of group 4. The inhibitory effect of the endothelium on serotonin-induced contractions was significantly increased in preparations of group 1 compared with those of groups 2 through 4. Indirect measurements of nitric oxide formation such as contractions evoked by NG-monomethyl-L-arginine (L-NMMA) and aortic cGMP content were also significantly enhanced in preparations from group 1 compared with those of groups 2 through 4. Moreover, because the relaxations to nitroglycerin and nitroprusside were similar in groups 1, 2, and 4 an alteration of the guanylate cyclase activity by ramipril treatment is quite unlikely. Thus long-term treatment with ramipril potentiates the endothelium-dependent responses in the rat aorta by enhancing nitric oxide availability.
为了确定慢性血管紧张素转换酶(ACE)抑制是否会在正常血压大鼠的主动脉中产生功能变化,将四组大鼠并行研究6周。第1组口服雷米普利,其余2周每天皮下注射β2-激肽拮抗剂HOE140 500微克/千克;第3组,每天口服肼屈嗪100毫克/千克,持续6周;第4组(对照组),在6周的最后2周皮下注射生理盐水。与第4组相比,第1组分离出的主动脉中缓激肽、乙酰胆碱和组胺诱导的舒张明显增强。在第3组中,尽管收缩压下降幅度与雷米普利治疗引起的相似,但对这三种内皮依赖性血管舒张剂的反应与第4组没有差异。在第2组中,缓激肽诱导的舒张完全被消除,而乙酰胆碱诱导的和组胺诱导的舒张与第4组相同。与第2至4组相比,第1组制剂中内皮对5-羟色胺诱导的收缩的抑制作用明显增强。与第2至4组相比,第1组制剂中间接测量一氧化氮生成的指标,如NG-单甲基-L-精氨酸(L-NMMA)诱发的收缩和主动脉环磷酸鸟苷(cGMP)含量也明显增强。此外,由于第1、2和4组对硝酸甘油和硝普钠的舒张作用相似,雷米普利治疗不太可能改变鸟苷酸环化酶活性。因此,雷米普利长期治疗通过增加一氧化氮的可用性增强大鼠主动脉的内皮依赖性反应。